Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Altimmune, Inc. ALT NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
43/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$20.00
+488.2%

Altimmune, Inc. (ALT) is a Biotechnology company in the Healthcare sector, currently trading at $3.40. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ALT = $20 (+488.2% upside).

Valuation: ALT trades at a trailing Price-to-Earnings (P/E) of -3.8 (S&P 500 average ~25).

Financials: revenue is $41,000, +4.8%/yr average growth. Net income is $88M (loss), growing at -1.5%/yr. Net profit margin is -214861% (negative). Gross margin is -173.2% (-161.2 pp trend).

Balance sheet: total debt is $36M against $225M equity (Debt-to-Equity (D/E) ratio 0.16, conservative). Current ratio is 18.55 (strong liquidity). Debt-to-assets is 12.7%. Total assets: $280M.

Analyst outlook: 12 / 15 analysts rate ALT as buy (80%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 30/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).

$20.00
▲ 488.24% Upside
Average Price Target
The 12-month price target for Altimmune, Inc. is $20.00.

ALT SharesGrow Score Overview

60/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ALT

✓
VALUE Pass
100/100
ALT trades at a trailing Price-to-Earnings (P/E) of -3.8 (S&P 500 average ~25). Forward PEG -0.53 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $20, implying +488.2% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
30/100
ALT: +4.8%/yr revenue is, -1.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ALT: Debt-to-Equity (D/E) ratio 0.16 (conservative), Current ratio is 18.55 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
94/100
Analyst outlook: 12 / 15 analysts rate ALT as buy (80%). Analyst consensus target is $20 (+488.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ALT: Net profit margin is -214861%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.87-7.73
Volume2.04M
Avg Volume (30D)3.9M
Market Cap$300.07M
Beta (1Y)0.34
Share Statistics
EPS (TTM)-1.00
Shares Outstanding$88.1M
IPO Date2017-05-26
Employees59
CEOJerome Benedict Durso
Financial Highlights & Ratios
Revenue (TTM)$41K
Gross Profit$-71K
EBITDA$-94.49M
Net Income$-88.09M
Operating Income$-94.49M
Total Cash$273.46M
Total Debt$35.69M
Net Debt$-8.07M
Total Assets$279.93M
Price / Earnings (P/E)-3.4
Price / Sales (P/S)7318.9
Analyst Forecast
1Y Price Target$20.00
Target High$20.00
Target Low$20.00
Upside+488.2%
Rating ConsensusBuy
Analysts Covering15
Buy 80% Hold 20% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS02155H2004

Price Chart

Track all markets on TradingView
ALT
Altimmune, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
2.87 52WK RANGE 7.73

People Also View

MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$518.58
-1.22%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 VKTX
VKTX
Viking Therapeutics, Inc.
$35.45
-0.20%
 ACAD
ACAD
ACADIA Pharmaceuticals Inc.
$21.76
-1.18%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 ARDX
ARDX
Ardelyx, Inc.
$6.30
-0.47%
 VSTM
VSTM
Verastem, Inc.
$6.33
+3.09%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message